Premium Serums Vaccines Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Premium Serums Vaccines Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Premium Serums Vaccines Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.3M Trade | TransData Nexus

Premium Serums Vaccines Private Limited

Indian Pharmaceutical Exporter · Other Specialist · $1.3M Total Trade · DGFT Verified

Premium Serums Vaccines Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.3M across 2 products in 1 therapeutic categories. Based on 44 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Serum ($837.6K), Antitoxin ($433.5K), .

Premium Serums Vaccines Private Limited — Export Portfolio & Destination Treemap

Premium Serums Vaccines Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Premium Serums Vaccines Private Limited? — Company Overview & Market Position

Premium Serums and Vaccines Private Limited, established on January 29, 2009, is a private unlisted company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24110MH2009PTC189968. Its authorized and paid-up capital stands at ₹2.00 crore each. The registered office is located at 406, B Wing, Highway Rose Co-Op Hsg Society 92, Dixit Road Extension, Vile Parle (East), Mumbai, Maharashtra 400057.

The company specializes in the manufacturing of biological products, including equine immunoglobulins and antivenoms, catering to healthcare applications. As of April 7, 2024, Premium Serums and Vaccines employed 82 professionals. The company's website, www.premiumserums.com, provides detailed information about its products and services.

What Does Premium Serums Vaccines Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Serum$837.6K 2Antitoxin

Product Portfolio — Top 2 by Export Value

Premium Serums Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Serum	Other	$837.6K	23	1.5%	4
2	Antitoxin	Other	$433.5K	21	2.1%	7

Premium Serums Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $1.3M. The top category is Other (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Premium Serums Vaccines Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Premium Serums and Vaccines operates manufacturing facilities in Maharashtra, India. The company specializes in the production of biological products, including equine immunoglobulins and antivenoms. Specific details regarding the locations and capacities of these manufacturing plants are not publicly disclosed. The facilities are designed to meet stringent quality standards, ensuring the safety and efficacy of their products.

3Key Leadership

The leadership team of Premium Serums and Vaccines Private Limited comprises:

Shyam Bhalchandra Dhawan: Director since January 29, 2009.

Girish Nathuram Kolwankar: Director since January 29, 2009.

Specific roles such as CEO or CFO are not publicly specified. The directors are responsible for overseeing the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Premium Serums Vaccines Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Premium Serums and Vaccines Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not publicly documented. The company primarily focuses on manufacturing biological products, including equine immunoglobulins and antivenoms, which are critical in healthcare applications. While the company has a global reach, specific regulatory filings, approvals, and market access statuses in these regions are not available in the public domain.

2Emerging Markets

The company's export data indicates shipments to various countries, suggesting a presence in emerging markets. However, specific details regarding its penetration in Africa, Latin America, and Southeast Asia are not publicly available. The company's focus on manufacturing biological products, including equine immunoglobulins and antivenoms, positions it to address healthcare needs in these regions. While the company strives to explore and integrate solutions with modern technology to provide affordable treatments, specific information about WHO prequalification or other certifications enabling access to these markets is not disclosed.

3Geographic Strategy

Premium Serums Vaccines Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Premium Serums and Vaccines Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on manufacturing biological products, including equine immunoglobulins and antivenoms, suggests that it may be subject to FDA regulations. However, without publicly available information, a comprehensive assessment of the company's FDA status cannot be provided.

2WHO & EU GMP

Specific information regarding Premium Serums and Vaccines Private Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's focus on manufacturing biological products, including equine immunoglobulins and antivenoms, suggests that it may adhere to international quality standards. However, without publicly available information, a comprehensive assessment of the company's compliance with WHO and EU GMP standards cannot be provided.

3CDSCO & Indian Regulatory

Premium Serums Vaccines Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Specific information regarding Premium Serums and Vaccines Private Limited's competitors in overlapping categories, market share comparisons, and head-to-head analyses is not publicly available. The company's focus on manufacturing biological products, including equine immunoglobulins and antivenoms, positions it in a niche market segment. However, without publicly available information, a comprehensive analysis of the competitive landscape cannot be provided.

2Key Differentiators

Premium Serums and Vaccines Private Limited differentiates itself through its focus on manufacturing biological products, including equine immunoglobulins and antivenoms, which are critical in healthcare applications. The company's commitment to quality and affordability positions it as a leading supplier in this niche market segment. However, without publicly available information, a comprehensive assessment of the company's unique strengths and competitive advantages cannot be provided.

3Strategic Position

Premium Serums and Vaccines Private Limited's strategic direction appears to focus on the manufacturing of biological products, including equine immunoglobulins and antivenoms. The company's commitment to quality and affordability suggests a focus on addressing critical healthcare needs. However, without publicly available information, a comprehensive assessment of the company's strategic position and future outlook cannot be provided.

Buyer Due Diligence Brief — Evaluating Premium Serums Vaccines Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Specific details regarding Premium Serums and Vaccines Private Limited's track record, export volume and consistency, and reliability indicators are not publicly available. The company's focus on manufacturing biological products, including equine immunoglobulins and antivenoms, suggests a commitment to quality and reliability. However, without publicly available information, a comprehensive assessment of the company's supplier performance cannot be provided.

2Certifications to Verify

Importers should verify the following certifications when considering Premium Serums and Vaccines Private Limited as a supplier:

FDA Facility Registration: To ensure compliance with U.S. regulations. Verification can be done through the FDA's official website.

WHO-GMP Certification: To confirm adherence to World Health Organization standards. Verification can be done through the WHO's official website.

Frequently Asked Questions — Premium Serums Vaccines Private Limited

How many pharmaceutical products does Premium Serums Vaccines Private Limited export from India?

Premium Serums Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Serum ($837.6K), Antitoxin ($433.5K). Total export value is $1.3M.

What is Premium Serums Vaccines Private Limited's total pharmaceutical export value?

Premium Serums Vaccines Private Limited's total pharmaceutical export value is $1.3M, based on 44 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Premium Serums Vaccines Private Limited cover?

Premium Serums Vaccines Private Limited exports across 1 therapeutic categories. The largest are Other (100.0%, 2 products).

Get Full Premium Serums Vaccines Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.